FDA issues complete response to Daiichi Sankyo-MSD's BLA for NSCLC [Yahoo! Finance]
![Yahoo! Finance](../../../Content/images/providers/Yahoo! Finance.png)
DAIICHI SANKYO S/ADR (DSNKY)
NASDAQ:AMEX Investor Relations:
daiichisankyo.com/media_investors/investor_relations/index.html
Company Research
Source: Yahoo! Finance
approval for patritumab deruxtecan (HER3-DXd) to treat non-small cell lung cancer (NSCLC). The BLA sought accelerated approval for the antibody-drug conjugate for adults with locally advanced or metastatic EGFR [epidermal growth factor receptor]-mutated NSCLC previously treated with two or more systemic therapies. The regulator highlighted inspection findings at a third-party manufacturing facility. The letter did not query the submitted efficacy or safety data for patritumab deruxtecan. Daiichi Sankyo research and development global head Ken Takeshita stated: “We will work closely with the FDA and the third-party manufacturer to address the feedback as quickly as possible in order to bring the first HER3-directed medicine to patients with previously-treated EGFR-mutated non-small cell lung cancer. “We remain confident in the ability to develop this medicine to its full potential.” The BLA was based on initial results from the multicentre, global, open-label, two-arm Phase
Show less
Read more
Impact Snapshot
Event Time:
DSNKY
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
DSNKY alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
DSNKY alerts
High impacting DAIICHI SANKYO S/ADR news events
Weekly update
A roundup of the hottest topics
DSNKY
News
- Arbitration Dispute Between Daiichi Sankyo and Seagen Ends [Yahoo! Finance]Yahoo! Finance
- Arbitration Dispute Between Daiichi Sankyo and Seagen EndsBusiness Wire
- Merck, Daiichi lung cancer therapy rejected in U.S. [Seeking Alpha]Seeking Alpha
- U.S. FDA declines to approve Merck-Daiichi's ‘guided missile' cancer drug [CNBC]CNBC
- Daiichi Sankyo peripheral T-cell lymphoma therapy approved in Japan [Yahoo! Finance]Yahoo! Finance